|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHML |
Gene summary for CHML |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHML | Gene ID | 1122 |
| Gene name | CHM like Rab escort protein | |
| Gene Alias | REP2 | |
| Cytomap | 1q43 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | P26374 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1122 | CHML | LZE2T | Human | Esophagus | ESCC | 2.30e-02 | 2.87e-01 | 0.082 |
| 1122 | CHML | LZE7T | Human | Esophagus | ESCC | 4.36e-03 | 2.45e-01 | 0.0667 |
| 1122 | CHML | LZE24T | Human | Esophagus | ESCC | 1.66e-10 | 2.51e-01 | 0.0596 |
| 1122 | CHML | P2T-E | Human | Esophagus | ESCC | 3.48e-09 | 1.70e-01 | 0.1177 |
| 1122 | CHML | P4T-E | Human | Esophagus | ESCC | 1.80e-02 | 8.72e-02 | 0.1323 |
| 1122 | CHML | P5T-E | Human | Esophagus | ESCC | 7.88e-08 | 2.07e-01 | 0.1327 |
| 1122 | CHML | P8T-E | Human | Esophagus | ESCC | 6.83e-12 | 7.34e-02 | 0.0889 |
| 1122 | CHML | P10T-E | Human | Esophagus | ESCC | 1.42e-10 | 1.44e-01 | 0.116 |
| 1122 | CHML | P11T-E | Human | Esophagus | ESCC | 1.78e-04 | 1.41e-01 | 0.1426 |
| 1122 | CHML | P12T-E | Human | Esophagus | ESCC | 1.75e-12 | 1.67e-01 | 0.1122 |
| 1122 | CHML | P16T-E | Human | Esophagus | ESCC | 2.97e-07 | 1.35e-01 | 0.1153 |
| 1122 | CHML | P21T-E | Human | Esophagus | ESCC | 3.17e-15 | 1.90e-01 | 0.1617 |
| 1122 | CHML | P22T-E | Human | Esophagus | ESCC | 2.42e-03 | 8.96e-02 | 0.1236 |
| 1122 | CHML | P23T-E | Human | Esophagus | ESCC | 1.67e-07 | 1.86e-01 | 0.108 |
| 1122 | CHML | P26T-E | Human | Esophagus | ESCC | 1.30e-10 | 1.40e-01 | 0.1276 |
| 1122 | CHML | P27T-E | Human | Esophagus | ESCC | 1.20e-02 | 6.42e-02 | 0.1055 |
| 1122 | CHML | P28T-E | Human | Esophagus | ESCC | 3.21e-10 | 2.02e-01 | 0.1149 |
| 1122 | CHML | P30T-E | Human | Esophagus | ESCC | 1.00e-09 | 3.58e-01 | 0.137 |
| 1122 | CHML | P31T-E | Human | Esophagus | ESCC | 2.55e-03 | 5.45e-02 | 0.1251 |
| 1122 | CHML | P32T-E | Human | Esophagus | ESCC | 1.51e-07 | 9.39e-02 | 0.1666 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHML | SNV | Missense_Mutation | novel | c.1060A>C | p.Ile354Leu | p.I354L | P26374 | protein_coding | tolerated(0.98) | benign(0.001) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHML | SNV | Missense_Mutation | c.539N>C | p.Lys180Thr | p.K180T | P26374 | protein_coding | tolerated(0.39) | benign(0.011) | TCGA-BH-A28Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CHML | insertion | Nonsense_Mutation | novel | c.1775_1776insCTCACTTGACCCTTGTAACTGATGAGGCAATGATG | p.Gln592HisfsTer8 | p.Q592Hfs*8 | P26374 | protein_coding | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| CHML | insertion | Nonsense_Mutation | novel | c.609_610insTGATGGTGATGATAAGCAGCCAGAG | p.Thr204Ter | p.T204* | P26374 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CHML | deletion | In_Frame_Del | c.1570_1611delNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN | p.Ser524_Glu537del | p.S524_E537del | P26374 | protein_coding | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |||
| CHML | insertion | Nonsense_Mutation | novel | c.1319_1320insATTCTTAGGAATTCCTAAGGAGAAACAGAGT | p.Tyr440Ter | p.Y440* | P26374 | protein_coding | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | ||
| CHML | SNV | Missense_Mutation | novel | c.1762C>T | p.His588Tyr | p.H588Y | P26374 | protein_coding | tolerated(0.61) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CHML | SNV | Missense_Mutation | c.1536T>G | p.Cys512Trp | p.C512W | P26374 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CHML | SNV | Missense_Mutation | rs374763241 | c.313G>A | p.Ala105Thr | p.A105T | P26374 | protein_coding | tolerated(0.13) | benign(0.07) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CHML | SNV | Missense_Mutation | novel | c.583G>C | p.Asp195His | p.D195H | P26374 | protein_coding | tolerated(0.05) | possibly_damaging(0.667) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |